Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods - Eris Pharmaceuticals (Australia)

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the quality, efficacy, and safety of therapeutic goods available in Australia. This Act was introduced to address the need for a comprehensive regulatory framework that ensures therapeutic goods, including medicines, medical devices, and blood products, are safe for use by the public. The legislation is administered by the Therapeutic Goods Administration (TGA), an agency within the Department of Health. The TGA operates under the authority of the Secretary, who is responsible for issuing licences to manufacturers. The policy objective of the Therapeutic Goods Act 1989 is to protect public health by ensuring that therapeutic goods are of acceptable quality and that their use does not pose unnecessary risks to consumers. By publishing the list of manufacturers granted licences, the Act facilitates transparency and accountability in the therapeutic goods supply chain.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation and control of therapeutic goods within Australia, encompassing a broad range of products such as medicines, medical devices, blood and tissues, and complementary medicines. The Act applies to persons and entities involved in the manufacture, importation, supply, and advertising of therapeutic goods. This includes individuals, companies, and other legal entities engaged in any aspect of the therapeutic goods supply chain, ensuring that such goods meet safety, quality, and efficacy standards. The Act’s jurisdictional reach is national, applying across all states and territories in the Commonwealth of Australia. The Act also extends its application through subordinate instruments, such as regulations and standards, which provide further detail and guidance on specific aspects of therapeutic goods regulation. While the Act broadly applies to all therapeutic goods, certain exclusions and exemptions may apply, such as those for small-scale, low-risk activities or specific types of goods as defined in the regulations. The publication of the list of manufacturers granted a licence, such as the one for Eris Pharmaceuticals (Australia) Pty Ltd, ensures transparency and compliance within the industry, reinforcing the Act’s commitment to public health and safety.

Key Provisions

The Therapeutic Goods Act 1989, specifically Section 38, authorises the Secretary of the Department of Health, Therapeutic Goods Administration to grant licences to entities for the manufacture of therapeutic goods. The act mandates the publication of such grants in the Commonwealth Gazette, providing transparency and public record of the entities authorised to manufacture these goods (Section 38(1)). In this instance, Eris Pharmaceuticals (Australia) Pty Ltd has been granted a licence to manufacture therapeutic goods, identified by the licence number MI-2013-LI-03598-1, with their manufacturing address listed as 6 Eastern Road, South Melbourne, VIC, 3205. This publication serves to inform the public and stakeholders of the specific entity that has been authorised to produce therapeutic goods. Entities granted a licence under the Therapeutic Goods Act 1989 are subject to a range of obligations and requirements. They must adhere to stringent quality standards and manufacturing practices as outlined in the Therapeutic Goods Regulations 1990. This includes ensuring that their manufacturing processes comply with Good Manufacturing Practice (GMP) standards, which are designed to maintain the quality and safety of therapeutic goods. The licence holders are also required to maintain detailed records of their manufacturing processes, quality control measures, and distribution chains. These records must be readily available for inspection by the Therapeutic Goods Administration to ensure ongoing compliance with the regulatory requirements. Breaches of the Therapeutic Goods Act 1989 and associated regulations can lead to significant legal consequences. If an entity fails to comply with the manufacturing standards or misrepresents their compliance status, they may face penalties. Under Section 26 of the Therapeutic Goods Act, the maximum penalty for contravening the Act can include fines up to $1,215,000 for a corporation and imprisonment for up to five years for an individual. Additionally, the Therapeutic Goods Administration can take action to suspend or revoke the licence, effectively halting the manufacture of therapeutic goods by the entity. Such actions are intended to protect public health and ensure that only compliant entities are permitted to manufacture therapeutic goods.